Jeppe Øvlesen
CEO and Board Member
SynAct Pharma
SynAct Pharma develops resomelagon, a once-daily oral selective melanocortin agonist that stimulates anti-inflammatory and inflammation resolution mechanisms without suppressing the immune system. This approach addresses the safety concerns associated with traditional anti-inflammatory treatments by promoting the body's natural ability to resolve excessive inflammation in conditions such as rheumatoid arthritis and respiratory insufficiency.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current anti-inflammatory treatments often suppress the immune system, leading to heightened risks of infection and other safety issues. This approach can hinder the body's ability to respond to new infections or injuries while addressing inflammation.
Solution
SynAct Pharma is developing resomelagon (AP1189), a once-daily, oral, selective melanocortin agonist designed to stimulate both anti-inflammatory and inflammation resolution mechanisms without suppressing the immune system. By harnessing the melanocortin system, resomelagon aims to resolve excessive inflammation safely, allowing the immune system to function effectively. The drug is currently being evaluated for the treatment of rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN), and respiratory insufficiency caused by viruses such as COVID-19.
Target Audience
The primary target audience includes patients with rheumatoid arthritis, idiopathic membranous nephropathy, and respiratory insufficiency, as well as the physicians who treat these conditions.
Features
- Once-daily oral administration for convenient dosing
- Selective melanocortin receptor stimulation to resolve inflammation
- Anti-inflammatory and pro-resolving activity without immunosuppression
- Targeted approach to resolve excessive inflammation safely
- Clinical trials underway for rheumatoid arthritis, idiopathic membranous nephropathy and respiratory insufficiency